論文

国際誌
2021年11月

Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report.

JTO clinical and research reports
  • Kei Kunimasa
  • Jiro Okami
  • Satoshi Takenaka
  • Keiichiro Honma
  • Yoji Kukita
  • Shigenori Nagata
  • Takahisa Kawamura
  • Takako Inoue
  • Motohiro Tamiya
  • Hanako Kuhara
  • Kazumi Nishino
  • Hideaki Tahara
  • Toru Kumagai
  • 全て表示

2
11
開始ページ
100235
終了ページ
100235
記述言語
英語
掲載種別
DOI
10.1016/j.jtocrr.2021.100235

A SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rapidly progressing subtype of lung cancer with a poor prognosis and causes early postoperative recurrence among operable patients. In this study, we present a case of SMARCA4-UT with vertebral and chest wall invasion that successfully underwent conversion surgery after treatment with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin. The surgical specimen comprised SMARCA4-deficient and SMARCA2-positive adenocarcinoma, confirming intratumor heterogeneity. Gene panel analysis revealed no substantial differences in mutant gene profiles among tumors and no differences in SMARCA2 mutations. Furthermore, no recurrence occurred for 9 months after surgery. Thus, this case illustrates the possibility of multidisciplinary treatment including neoadjuvant therapy with immunotherapy and conversion surgery for SMARCA4-UT.

リンク情報
DOI
https://doi.org/10.1016/j.jtocrr.2021.100235
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34746887
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551843
ID情報
  • DOI : 10.1016/j.jtocrr.2021.100235
  • PubMed ID : 34746887
  • PubMed Central 記事ID : PMC8551843

エクスポート
BibTeX RIS